American Trust’s Tandem Diabetes Care TNDM Stock Holding History

American Trust’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,163	Closed	-$252K	–	521
2022 Q1	$252K	Buy	+2,163	New	+$253K	0.02%	396

Other funds holding TNDM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

American Trust's TNDM Position: Q2 2022 in Review

American Trust sold out of Tandem Diabetes Care (TNDM) in Q2 2022, closing a stake of 2,163 shares — an estimated $252K sold.

American Trust first reported a position in TNDM in Q1 2022 and held it in 1 quarter. The position peaked at $252K in Q1 2022. 330 funds tracked by Wall St. Rank hold TNDM as of Q2 2022.

American Trust reported no remaining Tandem Diabetes Care position as of Q2 2022 after selling out during the quarter.
American Trust sold 2,163 Tandem Diabetes Care shares in Q2 2022, an estimated $252K.
American Trust first reported a position in Tandem Diabetes Care in Q1 2022 and held it in 1 quarter.
American Trust's Tandem Diabetes Care position peaked at $252K in Q1 2022.
330 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2022.

Based on American Trust's 13F filing for Q2 2022, filed 3 Oct 2022.